# Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.

- **DOI:** [10.1038/s41531-026-01341-8](https://doi.org/10.1038/s41531-026-01341-8)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** Plasma pTau217 retains strong amyloid-detection performance in biologically defined synuclein disease, but small selected validation cohorts limit clinical readiness.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41531-026-01341-8

## Key claims

1. Among all biomarkers, plasma pTau217 showed the best diagnostic performance (AUC = 0.92, 95% CI = 0.81-0.98).
   - Support: Supported
   - Type: Primary finding
   - Basis: the small discovery subset supports the direction, although pTau217 was comparable to Aβ42/40 and the abstract interval is inconsistent
   - Location: Abstract; Results, “Diagnostic accuracy of plasma biomarkers for detecting amyloid-β”; Figure 2A
2. Applying plasma pTau217 cut points to pre-screen clinically diagnosed LBD participants reduced the need for confirmatory amyloid-β PET or CSF in 41-56%.
   - Support: Tentative
   - Type: Secondary
   - Basis: a projected workflow effect from two small cohorts whose Table 2 counts do not reproduce the stated range
   - Location: Abstract; Results, “Validation of plasma pTau217 cut points”; Figure 3B; Table 2
3. The two-reference cut point model significantly improved the positive percentage agreement (PPA) (two-reference cut point vs. one-reference cut point in LBD-SU: 100% vs. 72.7%, and in LBD-SPIN: 86.4% vs. 68.8%).
   - Support: Tentative
   - Type: Secondary
   - Basis: the descriptive percentages favor two cut points, but no significance test or confidence intervals are reported
   - Location: Results, “Validation of plasma pTau217 cut points”; Table 2

## Strengths

- **Biological definition addresses the core gap** CSF α-synuclein SAA defines NSD in the discovery cohort, allowing biomarker performance to be assessed against underlying synuclein pathology rather than clinical diagnosis alone.
  - Dimension: contribution
  - Location: Methods, “Participants” and “CSF αSyn, Aβ42, and Aβ40”
- **Amyloid reference is PET calibrated** CSF Aβ42/40 classification was calibrated against centiloid-based PET thresholds in an independent subset, with an exploratory 24-centiloid analysis testing sensitivity to the reference definition.
  - Dimension: methodological rigour
  - Location: Methods, “Aβ PET”; Results, Figure 2C–D
- **Clear trial-prescreening application pathway** The Discussion identifies prescreening and stratification for LBD trials, including anti-amyloid studies requiring concomitant amyloid positivity, as concrete uses for pTau217.
  - Dimension: application pathway
  - Location: Discussion, paragraphs on clinical trials and the NIH RFA

## Limitations

- **Validation cohorts are small and heterogeneous** The external cohorts contain 29 and 44 participants, use PET versus cohort-specific CSF amyloid references, and include small positive-result denominators. These features limit precision and transferability of the proposed cut points.
  - Dimension: methodological rigour
  - Location: Results, validation cohort description; Table 2; Methods, “CSF αSyn, Aβ42, and Aβ40”
- **Headline quantities do not fully reconcile** The Abstract's pTau217 confidence interval differs from Figure 2A, while its 41–56% confirmatory-testing reduction cannot be reconstructed from Table 2. These discrepancies make the exact headline estimates uncertain.
  - Dimension: reporting
  - Location: Abstract; Results, Figure 2A, Figure 3B, and Table 2
- **Clinical conclusions exceed sampled populations** The Discussion acknowledges small, predominantly non-Hispanic White cohorts but still supports broad screening in NSD and clinically defined LBD. The cut points therefore require more representative prospective validation before routine use.
  - Dimension: positioning
  - Location: Discussion, limitations and summary paragraphs

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - Among all biomarkers, plasma pTau217 showed the best diagnostic performance (AUC = 0.92, 95% CI = 0.81-0.98): "Among all biomarkers, plasma pTau217 showed the best diagnostic performance (AUC = 0.92, 95% CI = 0.81-0.98)." (Abstract) vs "pTau217 AUC: 0.92, 95% CI: 0.85–1.00; Aβ42/40 AUC: 0.90, 95% CI: 0.81–0.98" (Results — Diagnostic accuracy of plasma biomarkers). Comparing the Abstract with the NSD+ Results shows that the Abstract uses the Aβ42/40 interval instead of the pTau217 interval, while both report pTau217 AUC 0.92. → Conclusion holds
- **Reporting and transparency:** Noted. Predictive-value terminology, the unreported inferential comparison underlying the PPA significance claim, and unstated biomarker-specific analytic sample sizes limit interpretation of the comparative performance results.
  - Ethics approval: declared
- **Reference integrity:** Clean
  - 67 references in manuscript
  - 66 of 66 checkable references found in an index
  - 1 are books, websites or datasets — counted, but not index-checkable
  - 1 DOI points to a different paper:
    - #57 Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. doi:10.1016/0022-3956(75)90026-6 (DOI resolves to: ““Mini-mental state”” — Folstein, 1975 (Journal of Psychiatric Research)) https://doi.org/10.1016/0022-3956(75)90026-6
  - Citation details diverge for 1 reference:
    - #54 McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and managament of dementia with Lewy bodies. Neurology. 2017;89(1):88–100. doi:10.1212/WNL.0000000000004058 (DOI resolves to: “Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium” — McKeith, 2017 (Neurology). Differs from the DOI’s record on: title, authors) https://doi.org/10.1212/wnl.0000000000004058
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
